The impact of the national reimbursement drug list negotiation policy on the accessibility and utilization of evolocumab and alirocumab in different levels of hospitals: an interrupted time series analysis.

Front Pharmacol · 2025 · PMC12497621 · PMID 41059208

Europe PMC DOI

hedged sentence

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

an increasing trendP < 0.001actually significant

Changes in DDDs Figures 2a,b show that before policy implementation, evolocumab exhibited an upward trend in DDDs (β 1 = 2931.563, P < 0.001), while alirocumab also demonstrated an increasing trend (β 1 = 833.907, P < 0.001), albeit less pronounced than that of evolocumab.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.